Finja Schweitzer1, Sarah Laurent1, Gereon R Fink1,2, Michael H Barnett3, Stephen Reddel4, Hans-Peter Hartung5, Clemens Warnke1. 1. Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne. 2. Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich, Germany. 3. Brain and Mind Centre. 4. Neuroimmunology Clinic, Concord Hospital, University of Sydney, Sydney, NSW, Australia. 5. Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Abstract
PURPOSE OF REVIEW: A variety of high-efficacy disease-modifying therapies (DMTs) are available for the treatment of multiple sclerosis (MS). After evaluation and approval by regulatory agencies, DMTs are likely to be administered to patients whose characteristics differ from those enrolled in clinical trials. This may contribute to the emergence of unexpected adverse events observed in the real-world setting. Higher age may be a relevant factor that could change the benefit-risk balance of DMTs, as it may associate with lower efficiency and higher frequency of adverse events. RECENT FINDINGS: The absolute and relative number of patients with MS who reach the age of 55 and higher increases. Growing evidence demonstrates lower efficacy of DMTs in older persons with MS. Specific risks during DMTs for MS, such as the risk of developing progressive multifocal leukoencephalopathy (PML) or the outcome following PML, have been associated with age. It is hypothesized that age-related and therapy-induced alterations to the immune system may have (super)additive effects, resulting in an acceleration of physiological immunosenescence and inflamm-aging. SUMMARY: In this article, we review the risks of high-efficacy DMTs in MS with a specific focus on age-related efficacy and risks, including opportunistic infections, malignancies, and autoimmune reactions.
PURPOSE OF REVIEW: A variety of high-efficacy disease-modifying therapies (DMTs) are available for the treatment of multiple sclerosis (MS). After evaluation and approval by regulatory agencies, DMTs are likely to be administered to patients whose characteristics differ from those enrolled in clinical trials. This may contribute to the emergence of unexpected adverse events observed in the real-world setting. Higher age may be a relevant factor that could change the benefit-risk balance of DMTs, as it may associate with lower efficiency and higher frequency of adverse events. RECENT FINDINGS: The absolute and relative number of patients with MS who reach the age of 55 and higher increases. Growing evidence demonstrates lower efficacy of DMTs in older persons with MS. Specific risks during DMTs for MS, such as the risk of developing progressive multifocal leukoencephalopathy (PML) or the outcome following PML, have been associated with age. It is hypothesized that age-related and therapy-induced alterations to the immune system may have (super)additive effects, resulting in an acceleration of physiological immunosenescence and inflamm-aging. SUMMARY: In this article, we review the risks of high-efficacy DMTs in MS with a specific focus on age-related efficacy and risks, including opportunistic infections, malignancies, and autoimmune reactions.
Authors: Anastasie M Dunn-Pirio; Benjamin M Heyman; Dan S Kaufman; Revere P Kinkel Journal: Curr Treat Options Neurol Date: 2019-10-17 Impact factor: 3.598
Authors: Le H Hua; Carrie M Hersh; Fan Tian; Ellen M Mowry; Kathryn C Fitzgerald Journal: Mult Scler Relat Disord Date: 2020-11-23 Impact factor: 4.339
Authors: Heidrun Golla; Kim Dillen; Martin Hellmich; Thomas Dojan; Solveig Ungeheuer; Petra Schmalz; Angelika Staß; Vanessa Mildenberger; Yasemin Goereci; Veronika Dunkl; Julia Strupp; Gereon R Fink; Raymond Voltz; Stephanie Stock; Oliver Cornely; Alexander Stahmann; Anne Müller; Peter Löcherbach; Lothar Burghaus; Volker Limmroth; Eckhard Bonmann; Kathrin Gerbershagen; Gereon Nelles; Thomas Joist; Judith Haas; Herbert Temmes; Clemens Warnke Journal: BMJ Open Date: 2022-01-25 Impact factor: 2.692
Authors: Gavin Giovannoni; Patricia K Coyle; Patrick Vermersch; Bryan Walker; Julie Aldridge; Axel Nolting; Andrew Galazka; Caroline Lemieux; Thomas P Leist Journal: Front Immunol Date: 2021-12-24 Impact factor: 7.561
Authors: Stanley L Cohan; Barry A Hendin; Anthony T Reder; Kyle Smoot; Robin Avila; Jason P Mendoza; Bianca Weinstock-Guttman Journal: CNS Drugs Date: 2021-07-06 Impact factor: 5.749
Authors: Boris A Kallmann; Stefan Ries; Jennifer S Kullmann; Laura M Quint; Ulrich Engelmann; Andrew Chan Journal: Ther Adv Neurol Disord Date: 2021-05-18 Impact factor: 6.570